Recordati Industria Chimica E Farmaceutica S.p.a.

Sergio Menegon

Carlo Riva

Davide Graziani

Patrizia Angelico

Marco Barchielli

Fabio Berlati

Diego Provvedini

Valerio Tazzari

Alberto Mattei

Pierluigi Farina

This invention relates to compounds of formula I; and their use as antagonists of P2Xand P2Xreceptor activity, pharmaceutical compositions comprising such compounds, and methods of treatment therewith. Compounds of the invention can be used for the treatment and/or prevention of pain and chronic pain and tolerance to analgesic, respiratory disorders and dysfunctions, and treatment of overactive bladder, bladder pain syndrome, dysuria and in general in genitourinary diseases, cardiovascular disorders and more in general for the potential treatment of visceral organ diseases and disorders characterized by the involvement of P2Xand P2Xreceptors.

P2Xreceptor antagonists

Disclosed are triazole, imidazole and pyrrole condensed piperazine derivatives and their use as allosteric modulators of mGlus receptor activity, pharmaceutical compositions comprising such compounds, and methods of treatment therewith. Compounds of the invention can be used for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related either directly or indirectly to glutamate dysfunction, i.e., disorders treatable by positive allosteric modulation (PAM) or by negative allosteric modulation (NAM) of mGluR. 

Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of mGlu5 receptors

The present invention relates to a pharmaceutical formulation suitable for parenteral administration containing carglumic acid and a buffering agent having a pKfrom 5.5 to 9.0 at 25&#xb0; C.; according to an embodiment, the buffering agent may have a pKfrom 7.5 to 8.5, preferably a pKof about 8.07, such as trometamol. The formulation may also contain at least one bulking agent, such as mannitol. The invention also includes a method for manufacturing a lyophilised sterile formulation by freeze-drying a water solution containing carglumic acid, a buffering agent having a pKfrom 5.5 to 9.0 at 25&#xb0; C., preferably from 7.5 to 8.5, and optionally a bulking agent to obtain a freeze-dried powder.

Pharmaceutical parenteral formulation containing carglumic acid

Growing community of inventors

Milan, Italy

Sergio Menegon